Publication details
Xolair v léčbě chronické spontánní kopřivky
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Conference abstract |
| Citation | |
| Description | Omalizumab (humanised anti-IgE monoclonal antibody) has been approved for the treatment of chronic spontaneous urticaria (CSU) as a 3rd line treatment in adult and adolescent patients with insufficient response to H1 antihistamines. So far we have treated 12 CSU patients with omalizumab. Due to the marked variability of the response to omalizumab, we would welcome the possibility of a more flexible treatment scheme. |